Method of treating ocular neovascular disease
By overexpressing PKM1 and/or PKM2 in retinal cells, and utilizing AAV vectors and neuron-specific promoters, the limitations of VEGF drug therapy for ocular neovascularization have been overcome, achieving safe and efficient inhibition of neovascularization and improvement of leakage.
CN122272846APending Publication Date: 2026-06-26TIANJIN EYE HOSPITAL
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- TIANJIN EYE HOSPITAL
- Filing Date
- 2026-04-29
- Publication Date
- 2026-06-26
AI Technical Summary
Technical Problem
While existing anti-vascular endothelial growth factor (VEGF) drugs are effective in treating ocular neovascularization, long-term and repeated intraocular injections increase the risk of local complications and have limited efficacy.
Method used
By increasing the expression levels of pyruvate kinase M1 (PKM1) and/or M2 (PKM2), PKM1 and/or PKM2 are overexpressed in retinal cells using AAV vectors and neuron-specific promoters, angiogenesis and vascular leakage are inhibited.
Benefits of technology
It significantly inhibits retinal neovascularization, improves fundus neovascular leakage, achieves long-term therapeutic effect with high safety, and does not cause systemic abnormalities or intraocular inflammation.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122272846A_ABST
Abstract
This invention provides the use of a reagent for increasing pyruvate kinase expression levels in the preparation of a drug for treating ocular neovascularization in subjects. The drug provides long-acting treatment with a high safety profile.
Need to check novelty before this filing date? Find Prior Art